Literature DB >> 19947800

Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.

Stephen B Woolley1, Alex A Cardoni, John W Goethe.   

Abstract

STUDY
OBJECTIVE: To determine the prevalence, over 40 years, of using the last-observation-carried-forward (LOCF) imputation method in clinical trials, the association between use of LOCF and how the trials were conducted, and the extent of information about attrition and LOCF use in published reports.
DESIGN: Retrospective analysis of the reports of randomized antidepressant efficacy trials published over a 40-year period (1965-2004). DATA SOURCES: MEDLINE database, Cochrane reviews, reference- and bibliography-based manual search, and publication list services.
MEASUREMENTS AND MAIN RESULTS: A total of 352 trials met the following criteria for analysis: antidepressant comparative efficacy trial, randomized design, patients with major depressive disorder, English-language article, published during 1965-2004, and first report of a trial. Design, attrition, and data analysis characteristics were recorded by investigators and trained assistants. Analyses included descriptive statistics of the trial size, duration, and number of patients who dropped out in LOCF versus non-LOCF studies, as well as the extent to which dropouts and the potential bias associated with attrition was discussed in the published report. The frequency of published antidepressant clinical trials increased from less than 1 trial/year (1965-1974) to 19 trials/year (1990-1994). Trials using the LOCF method were significantly larger than non-LOCF trials (p<0.01), and the proportion of subjects dropping out was significantly greater (p<0.05) in LOCF versus non-LOCF trials. The proportion of subjects dropping out remained relatively constant over time (approximately 30%) but was significantly greater among LOCF (30.9%) than non-LOCF (28.8%) trials (p<0.01). The LOCF study articles were more likely to report dropouts, but only 7% of these articles reported outcomes recorded for subjects before they dropped out. Less than 16% of articles discussed bias associated with dropouts, 6.8% discussed the direction of bias, and only about 2% suggested the magnitude of the bias.
CONCLUSION: The percentage of clinical antidepressant trials using the LOCF method and the percentage of study subjects' data imputed by using LOCF increased many-fold during 1965-2004. Published reports of trials provided little information to allow readers to assess possible bias introduced by use of the LOCF method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19947800     DOI: 10.1592/phco.29.12.1408

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review.

Authors:  Juan Undurraga; Ross J Baldessarini
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Development and Validation of Multi-Stage Prediction Models for Pre-eclampsia: A Retrospective Cohort Study on Chinese Women.

Authors:  Zeyu Tang; Yuelong Ji; Shuang Zhou; Tao Su; Zhichao Yuan; Na Han; Jinzhu Jia; Haijun Wang
Journal:  Front Public Health       Date:  2022-05-30

3.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

4.  Cost-utility analysis of a dance intervention for adolescent girls with internalizing problems.

Authors:  Anna Philipsson; Anna Duberg; Margareta Möller; Lars Hagberg
Journal:  Cost Eff Resour Alloc       Date:  2013-02-20

5.  Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Authors:  Erick H Turner; Daniel Knoepflmacher; Lee Shapley
Journal:  PLoS Med       Date:  2012-03-20       Impact factor: 11.069

6.  Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.

Authors:  Kaida Jiang; Lingjiang Li; Xueyi Wang; Maosheng Fang; Jianfei Shi; Qiuyun Cao; Jincai He; Jinan Wang; Weihao Tan; Cuili Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-17       Impact factor: 2.570

Review 7.  Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis.

Authors:  Klaus Munkholm; Asger Sand Paludan-Müller; Kim Boesen
Journal:  BMJ Open       Date:  2019-06-27       Impact factor: 2.692

8.  Cost-utility analysis of a randomized controlled weight loss trial among lactating overweight/obese women.

Authors:  Lars A Hagberg; Hilde K Brekke; Fredrik Bertz; Anna Winkvist
Journal:  BMC Public Health       Date:  2014-01-15       Impact factor: 3.295

9.  Impact of a lay-led home-based intervention programme on quality of life in community-dwelling pre-frail and frail older adults: a randomized controlled trial.

Authors:  A Kapan; E Winzer; S Haider; S Titze; K Schindler; C Lackinger; T E Dorner
Journal:  BMC Geriatr       Date:  2017-07-19       Impact factor: 3.921

10.  Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients.

Authors:  Michele F Eisenga; Antonio W Gomes-Neto; Marco van Londen; Aaltje L Ziengs; Rianne M Douwes; Suzanne P Stam; Maryse C J Osté; Tim J Knobbe; Niek R Hessels; Anne M Buunk; Coby Annema; Marion J Siebelink; Emoke Racz; Jacoba M Spikman; Frank A J A Bodewes; Robert A Pol; Stefan P Berger; Gea Drost; Robert J Porte; Henri G D Leuvenink; Kevin Damman; Erik A M Verschuuren; Vincent E de Meijer; Hans Blokzijl; Stephan J L Bakker
Journal:  BMJ Open       Date:  2018-12-31       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.